4 - OmniAb, Inc. (0001846253) (Issuer)

4 - OmniAb, Inc. (0001846253) (Issuer)

SC 13G/A - OmniAb, Inc. (0001846253) (Subject)

SC 13D/A - OmniAb, Inc. (0001846253) (Subject)

Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today OmniAb, Inc. (NASDAQ:OABI) today reported financial results for the three and nine months ended September 30, 2024, and provided operating and partner program updates. "We are pleased to report another successful quarter demonstrating our continued commitment to innovation with the expansion of our technology platform and a growing partnership portfolio. Third quarter results reflect consistent growth across key metrics, driven by our planned initiatives and the dedication of our team," said Matt Foehr, Chief Executive Officer of OmniAb. "Our business is well capitalized, and we have a highly scalable model with cutting-

OmniAb, Inc. (NASDAQ:OABI) will report financial results for the three and nine months ended September 30, 2024 after the close of the U.S. financial markets on Tuesday, November 12, 2024 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Conference Call and Webcast Information What:   OmniAb conference call to discuss third quarter financial results and business updates       Date:   Tuesday, November 12, 2024       Time:   4:30 p.m. Eastern time (1:30 p.m. Pacific time)       Phone:   U.S. (800) 549 8228     International (289) 819 1520     Conference ID is 943

Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today OmniAb, Inc. (NASDAQ:OABI) today reported financial results for the three and six months ended June 30, 2024, and provided operating and partner program updates. "Second quarter results were in-line with our expectations and support our view of the full year. We advanced our business by adding new partnerships and programs as existing partners made important clinical progress in their respective programs," said Matt Foehr, Chief Executive Officer of OmniAb. "With recent momentum in business development, 2024 has the potential to be a record year in terms of deal flow, which we believe is driven by the quality and differe

OmniAb, Inc. (NASDAQ:OABI) will report financial results for the three and six months ended June 30, 2024 after the close of the U.S. financial markets on Thursday, August 8, 2024 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Conference Call and Webcast Information What:   OmniAb conference call to discuss financial results and business updates       Date:   Thursday, August 8, 2024       Time:   4:30 p.m. Eastern time (1:30 p.m. Pacific time)       Conference Call:   U.S. (800) 549 8228     Interna

Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today OmniAb, Inc. (NASDAQ:OABI) today reported financial results for the three months ended March 31, 2024, and provided operating and partner program updates. "The OmniAb team continued to make great progress this past quarter in advancing and expanding our portfolio and partnership base. We added three new platform license agreements in the first quarter, bringing our total active partners to 80, net of attrition," said Matt Foehr, Chief Executive Officer of OmniAb. "We have built our company upon a differentiated suite of technologies and a highly scalable and leverageable business model, and our growth during the past 18

OmniAb, Inc. (NASDAQ:OABI) will report financial results for the three months ended March 31, 2024 after the close of the U.S. financial markets on Thursday, May 9, 2024 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Conference Call and Webcast Information What:   OmniAb conference call to discuss financial results and business updates       Date:   Thursday, May 9, 2024       Time:   4:30 p.m. Eastern time (1:30 p.m. Pacific time)       Conference Call:   U.S. (800) 549 8228     International +1 (28

Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today OmniAb, Inc. (NASDAQ:OABI) today reported financial results for the three and 12 months ended December 31, 2023, and provided operating and partner program updates. "2023 was a year of significant expansion of OmniAb's partnership base and pipeline programs as we continued to execute against our plan, while key partner programs made significant progress despite last year's sector-related headwinds. Partners exceeded our expectations regarding the number of new programs entering the clinic, with a total of six new entrants last year," said Matt Foehr, Chief Executive Officer of OmniAb. "In addition, we successfully launch

OmniAb, Inc. (NASDAQ:OABI) will report financial results for the three and 12 months ended December 31, 2023 after the close of the U.S. financial markets on Wednesday, March 20, 2024 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Conference Call and Webcast Information What:   OmniAb conference call to discuss financial results and business updates       Date:   Wednesday, March 20, 2024       Time:   4:30 p.m. Eastern time (1:30 p.m. Pacific time)       Conference Call:   U.S. (888) 259-6580     In

Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today OmniAb, Inc. (NASDAQ:OABI) today reported financial results for the three and six months ended June 30, 2023, and provided operating and partner program updates. "Our business continued to grow and perform well during the second quarter with advancements in business development and progress across partner programs. The addition of four new partners during the quarter, including Merck & Co. and Neurocrine Biosciences, highlights the relevance and robustness of our technology platform. Existing partners made progress with two new programs entering the clinic and the total number of active programs increased to 305," said M

OmniAb, Inc. (NASDAQ:OABI) will report financial results for the three and six months ended June 30, 2023 after the close of the U.S. financial markets on Thursday, August 10, 2023 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Conference Call and Webcast Information   What: OmniAb conference call to discuss financial results and business updates   Date: Thursday, August 10, 2023   Time: 4:30 p.m. Eastern time   Conference Call: U.S. (888) 396-8049 International +1 (416) 764-8646 Conference ID is 10758721   Webcast:

OmniAb, Inc. (NASDAQ:OABI) today announced the appointment of Steve Love to its Board of Directors. Mr. Love has more than 30 years of financial experience including more than 13 years serving in Chief Financial Officer positions, and will serve on OmniAb's Audit Committee as Chair. With this appointment the OmniAb Board returns to seven directors, including five independent directors. "We are delighted Steve has agreed to join the OmniAb Board of Directors and extend a warm welcome," stated John Higgins, OmniAb Board Chair. "Steve's vast financial expertise, technical knowledge and experience leading technology and biotechnology companies will be valuable assets as we grow and expand our

10-Q - OmniAb, Inc. (0001846253) (Filer)

8-K - OmniAb, Inc. (0001846253) (Filer)

10-Q - OmniAb, Inc. (0001846253) (Filer)

8-K - OmniAb, Inc. (0001846253) (Filer)

8-K - OmniAb, Inc. (0001846253) (Filer)

10-Q - OmniAb, Inc. (0001846253) (Filer)

8-K - OmniAb, Inc. (0001846253) (Filer)

ARS - OmniAb, Inc. (0001846253) (Filer)

DEFA14A - OmniAb, Inc. (0001846253) (Filer)

DEF 14A - OmniAb, Inc. (0001846253) (Filer)

RBC Capital Mkts initiated coverage of OmniAb with a rating of Outperform and set a new price target of $6.00

The Benchmark Company initiated coverage of OmniAb with a rating of Buy and set a new price target of $8.00

Craig Hallum initiated coverage of OmniAb with a rating of Buy and set a new price target of $10.00

Cowen initiated coverage of OmniAb with a rating of Outperform and set a new price target of $10.00

H.C. Wainwright initiated coverage of OmniAb with a rating of Buy and set a new price target of $11.00

Engineered chickens producing single domain antibodies (sdAbs) provided the scientific foundation for OmnidAb™, the Company's novel transgenic chicken platform launched in 2023 that generates fully human and stabilized sdAbs

Technical synergies between xPloration, OmniFlic®, OmniClic® and OmniDeep®enable new bispecific antibody discovery workflows for OmniAb's partnersOmniAb, Inc. (NASDAQ:OABI) today announced its participation in the 20th Annual PEGS Boston – The Essential Protein & Antibody Engineering Summit underway at the Omni Hotel. Earlier today the Company presented an overview of xPloration, a high-throughput single B-cell screening platform that leverages machine learning and Artificial Intelligence (AI), in a presentation titled "Deep Screening in Harmony with Artificial Intelligence for Bispecific Antibody Discovery."

Benchmark analyst Robert Wasserman reiterates OmniAb (NASDAQ:OABI) with a Buy and maintains $8 price target.

OmniAb (NASDAQ:OABI) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.16) by 18.75 percent. This is a 216.67 percent decrease over losses of $(0.06) per share from the same period last year. The company reported quarterly sales of $3.801 million which missed the analyst consensus estimate of $5.868 million by 35.22 percent. This is a 77.53 percent decrease over sales of $16.919 million the same period last year.

Truist Securities analyst Robyn Karnauskas maintains OmniAb (NASDAQ:OABI) with a Buy and maintains $10 price target.

Although U.S. stocks closed lower on Monday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform. Hallador Energy The Trade: Hallador Energy Company (NASDAQ:HNRG) Director Charles Ray Wesley IV acquired a total of 46,100 shar

Benchmark analyst Robert Wasserman reiterates OmniAb (NASDAQ:OABI) with a Buy and maintains $8 price target.

HC Wainwright & Co. analyst Joseph Pantginis reiterates OmniAb (NASDAQ:OABI) with a Buy and maintains $11 price target.

RBC Capital analyst Conor McNamara reiterates OmniAb (NASDAQ:OABI) with a Outperform and maintains $7 price target.

OmniAb (NASDAQ:OABI) reported its Q4 earnings results on Wednesday, March 20, 2024 at 04:05 PM. Here's what investors need to know about the announcement. Earnings OmniAb beat estimated earnings by 7.000000000000001%, reporting an EPS of $-0.14 versus an estimate of $-0.15. Revenue was down $30.52 million from the same period last year. Past Earnings Performance Last quarter the company missed on EPS by $0.02 which was followed by a 3.0% drop in the share price the next day. Here's a look at OmniAb's past performance: Quarter Q3 2023 Q2 2023 Q1 2023 Q4 2022 EPS Estimate -0.14 -0.12 -0.03 0.02 EPS Actual -0.16 -0.15 -0.06 0.07 Revenue Estimate 10.33M 11.49M 18.98M 24.73M Revenue